JP2022085871A - Oral composition - Google Patents

Abstract

To provide an oral composition having excellent stability (storage stability) of vitamin B5 or a derivative thereof, having pharmaceutical stability, and giving a high feeling of retention in the oral cavity.SOLUTION: The oral composition comprises (A) vitamin B5 or a derivative thereof, (B) a nonionic surfactant, and (C) a hydrocarbon oil in liquid state at 25°C. The content of the component (C) is 0.1 to. 9 mass%.SELECTED DRAWING: None

Description

The present invention relates to an oral composition having excellent stability of vitamin B5 or a derivative thereof.

Vitamin B5 or its derivatives, such as panthenol, are known to have the effect of activating cells and promoting the proliferation of fibroblasts, enhancing metabolism and suppressing inflammation of the skin and the like, and further, a moisturizer. It is also used in cosmetics, shampoo, etc. for the purpose of preventing itching, sunburn skin care, and scalp care as a scalp protectant. Vitamin B5 or its derivative can be used for the purpose of improving metabolism and anti-inflammatory in oral tissues by blending it in an oral composition, but it is generally unstable in a state of being dissolved in water, and it can be used as an aqueous preparation. When it is blended, its effect decreases with time, and there is a problem that it is particularly difficult to blend it as an active ingredient in an aqueous oral composition.

As a past attempt to stabilize pantenol in an aqueous solution, a method of using boric acid in combination (Patent Document 1; Japanese Patent Application Laid-Open No. 05-017355), boric acid and a compound having three or more hydroxyl groups in one molecule. (Patent Document 2; JP-A-2002-265357), a method in which allantoin and diphenhydramine are used in combination (Patent Document 3; JP-A-2006-335676), and a method in which ibuprofen piconol is used in combination (Patent Document). 4; Japanese Patent Application Laid-Open No. 2015-010060) has been proposed. However, none of these methods can be applied to oral compositions because they use pharmaceutical ingredients and the like that cannot be used for oral applications.
On the other hand, a method of adding pantenol to an aqueous oral composition to improve its stability, glycyrrhizinate or cetylpyridinium chloride, or a method in which both are used in combination (Patent Documents 5 to 7; JP-A-2016-). No. 175875, Japanese Patent Application Laid-Open No. 2016-179967, Japanese Patent Application Laid-Open No. 2016-185915), and examples of compositions in various forms such as dentifrices are described. However, these techniques may limit the composition due to the limitation of the active ingredients that can be blended, and the development of a new technique for stably blending vitamin B5 or a derivative thereof in the oral composition has become an issue. rice field.

Japanese Unexamined Patent Publication No. 05-017355 Japanese Unexamined Patent Publication No. 2002-265357 Japanese Unexamined Patent Publication No. 2006-335676 Japanese Patent Application Laid-Open No. 2015-010060 Japanese Unexamined Patent Publication No. 2016-175875 Japanese Unexamined Patent Publication No. 2016-179967 Japanese Unexamined Patent Publication No. 2016-185915 Japanese Unexamined Patent Publication No. 2007-8831

The present invention has been made in view of the above circumstances, and an object of the present invention is to provide an oral composition having excellent stability of vitamin B5 or a derivative thereof and also having pharmaceutical stability.

As a result of diligent studies to achieve the above object, the present inventors combined a nonionic surfactant and a specific amount of a specific hydrocarbon oil in an oral composition containing vitamin B5 or a derivative thereof. When blended, the stability of vitamin B5 or its derivative is remarkably improved, and it is stably blended over time to have excellent storage stability, and the appearance of the formulation is kept stable, and the formulation is stable and high. It has been found that it is possible to give a feeling of retention in the oral cavity, and the present invention has been made.

That is, in the present invention, (A) vitamin B5 or a derivative thereof, (B) a nonionic surfactant, and (C) a hydrocarbon oil liquid at 25 ° C. are contained, and the content of the component (C) is in a specific range. By using the internal oral composition, it is possible to obtain an oral composition that has excellent stability (storage stability) of the component (A), has pharmaceutical stability, and gives a high feeling of retention in the oral cavity. Can be done.
More specifically, when the component (A) is added to an aqueous oral composition, for example, a dentifrice composition, even if the component (B) known as a solubilizer is added, the component (A) remains over time. It decomposed and its content gradually decreased, and the feeling of retention in the oral cavity of the preparation was also low. On the other hand, when the component (C) is added to the dentifrice composition containing the component (A), there arises a problem that the larger the amount of the component (C), the more liquid separation occurs over time and the appearance of the formulation is significantly deteriorated. rice field. However, according to the present invention, the components (B) and (C) form a stable emulsified form within a specific range of the content of the component (C), whereby the component (A) is for an aqueous oral system. Even if it is blended in the composition, the pharmaceutical product stability is ensured without deteriorating the appearance of the pharmaceutical product due to liquid separation or the like over time, and the component (A) is stably blended over time to provide excellent storage stability. In addition, it was also possible to impart a high feeling of retention in the oral cavity, which is felt to be effective by covering the oral cavity, particularly the oral mucosa, with the pharmaceutical product.
Furthermore, in oral compositions such as dentifrice compositions, water-insoluble powders such as silicon dioxide, which are generally used as binders and abrasives, also contribute to ensuring the stability of the composition. The smaller the blending amount, the lower the stability tends to be. However, according to the oral composition of the present invention, the blending amount of the water-insoluble powder, silicon dioxide, is relatively small, and further, the abrasive is blended. Even if it is not, the stability (storage stability) of the component (A) is excellent and the formulation stability can be obtained.
In addition, Patent Document 8 (Japanese Unexamined Patent Publication No. 2007-8831) is an improvement of the therapeutic effect on stomatitis with a coating agent by using panthenol in combination with allantoin or a derivative thereof, and the preparation described as an example thereof is pan. It contains tenol, polyoxyethylene hydrogenated castor oil, sorbitan monostearate and light liquid paraffin, and the amount of light liquid paraffin is 13 g (13% by mass) with respect to 100 g of the total amount of the preparation. On the other hand, the present invention is an oral composition, particularly a dentifrice composition, in which the content of the component (C) is 9% by mass or less by combining the components (A), (B) and (C). In (A), the stability of the preparation is particularly good while ensuring the stability (storage stability) of the component, and further, a high feeling of retention in the oral cavity after rinsing with water can be imparted. (C) It exerts a particularly remarkable action and effect which cannot be obtained when the content of the component is more than 9% by mass.

Therefore, the present invention provides the following oral compositions.
[1]
(A) Vitamin B5 or its derivatives,
An oral composition comprising (B) a nonionic surfactant and (C) a hydrocarbon oil liquid at 25 ° C., and containing 0.1 to 9% by mass of the component (C). ..
[2]
The oral composition according to [1], wherein the content of the component (A) is 0.1 to 5% by mass, and the content of the component (B) is 0.5 to 10% by mass.
[3]
(D) The oral composition according to [1] or [2], which contains a solid higher alcohol at 25 ° C.
[4]
(D) The oral composition according to [3], wherein the content of the component is 0.5 to 10% by mass.
[5]
The oral composition according to [3] or [4], wherein (C) / (D) is 0.1 to 10 in mass ratio.
[6]
The oral composition according to any one of [3] to [5], wherein ((C) + (D)) / (B) has a mass ratio of 0.5 to 8.
[7]
The oral composition according to any one of [1] to [6], which further contains (E) silicic anhydride.
[8]
(E) The oral composition according to [7], wherein the content of the component is 1 to 10% by mass.
[9]
The oral composition according to any one of [1] to [8], which is a dentifrice composition.

According to the present invention, it is possible to provide an oral composition (A) having excellent stability (storage stability) of vitamin B5 or a derivative thereof, having pharmaceutical stability, and giving a high feeling of retention in the oral cavity. The oral composition of the present invention can stably and effectively exert actions such as improvement of metabolism of oral tissue and anti-inflammatory by the component (A), and prevent or suppress periodontal diseases such as gingival inflammation. It is effective for use.

Hereinafter, the present invention will be described in more detail.
The oral composition of the present invention contains (A) vitamin B5 or a derivative thereof, (B) a nonionic surfactant, and (C) a hydrocarbon oil liquid at 25 ° C.

(A) Vitamin B5 or a derivative thereof has a tissue repairing action by cell activation, and is an active ingredient for improving metabolism of oral tissues, anti-inflammatory and the like.
Examples of vitamin B5 or a derivative thereof include pantothenic acid, salts such as an alkali metal salt of pantothenic acid, and panthenol which is an alcohol analog of pantothenic acid. Among them, panthenol is preferable from the viewpoint of tissue repair.

(A) The blending amount of vitamin B5 or a derivative thereof is preferably 0.1 to 5% (mass%, the same applies hereinafter) of the entire composition, more preferably 0.2 to 1.0%, still more preferably 0. It is 3 to 0.5%. When the blending amount is within the above range, the effect of the component (A) can be sufficiently obtained, and the stability of the component (A) (storage stability, hereinafter abbreviated as "stability of the component (A)") and The stability of the pharmaceutical product is improved, and the feeling of retention in the oral cavity of the pharmaceutical product can be obtained.

In the present invention, by using (B) a nonionic surfactant and (C) a hydrocarbon oil liquid at 25 ° C. in combination, this combined system forms a stable emulsified form and is stable together with the component (A). It is emulsified into an excellent product (A) and the product stability is obtained. If the component (B) is not contained, the drug product uniformity cannot be obtained, and if the component (C) is not contained, the product (A) is not contained. ) The stability of the ingredients is inferior.

The (B) nonionic surfactant has the effect of suppressing the occurrence of liquid separation and the like due to the component (C) over time to improve the pharmaceutical stability, and also improving the stability of the component (A) over time. Play.
(B) As the nonionic surfactant, polyoxyethylene sorbitan fatty acid ester, sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, sucrose fatty acid ester, alkyl glycoside, polyoxyethylene-polyoxypropylene. Examples thereof include block copolymers, polyoxyethylene ethers of glycerin esters, fatty acid alkyrrole amides, glycerin fatty acid esters, and the like, and these may be used alone or in combination of two or more. Among them, polyoxyethylene sorbitan fatty acid ester, sorbitan fatty acid ester, and polyoxyethylene cured castor oil are preferable, and polyoxyethylene sorbitan fatty acid ester and sorbitan fatty acid ester are more preferable. It is most preferable to use polyoxyethylene sorbitan fatty acid ester and sorbitan fatty acid ester in combination.
Further, from the viewpoint of the stability of the component (A) and the stability of the preparation, the polyoxyethylene sorbitan fatty acid ester preferably has 12 to 20 carbon atoms of the fatty acid, and the average number of moles of ethylene oxide added is 10 to 30. The one is preferable. Specific examples thereof include polyoxyethylene (20) sorbitan monostearate and the like. The sorbitan fatty acid ester preferably has 12 to 20 carbon atoms of the fatty acid, and specific examples thereof include sorbitan monostearate. The polyoxyethylene cured castor oil preferably has an average number of moles of ethylene oxide added of 20 to 100.

The blending amount of the (B) nonionic surfactant is preferably 0.5 to 10%, more preferably 1 to 5%, still more preferably 2 to 4% of the entire composition. When the blending amount is 0.5% or more, the stability of the component (A) and the formulation stability are sufficiently obtained, and when the blending amount is 10% or less, the formulation stability is sufficiently ensured, and the oral cavity of the formulation is obtained. The feeling of staying inside is ensured.

(C) The hydrocarbon oil liquid at 25 ° C., when used in combination with the component (B), has the effect of improving the stability of the component (A) over time, and also has the effect of enhancing the feeling of retention in the oral cavity of the preparation. Play.
Examples of the hydrocarbon oil liquid at 25 ° C. include liquid paraffin, light liquid paraffin, squalane and the like, and these may be used alone or in combination of two or more. Among them, liquid paraffin (viscosity 37 mm ² / s or more (37.8 ° C), 17th revised Japanese Pharmacopoeia), light liquid paraffin (viscosity 37 mm ² / s or less (37.8 ° C), 17th revised Japanese Pharmacopoeia). Is preferable, and light liquid paraffin is more preferable in terms of formulation stability.
Such hydrocarbon oils liquid at 25 ° C. are specifically liquid paraffin (liquid paraffin No. 350S manufactured by Sanko Chemical Industry Co., Ltd.) and light liquid paraffin (No. 70- manufactured by Sanko Chemical Industry Co., Ltd.). Commercially available products such as S) and light liquid paraffin (Hicol M72 manufactured by Kaneda Co., Ltd.) can be used.

(C) The blending amount of the hydrocarbon oil liquid at 25 ° C. is 0.1 to 9%, preferably 1 to 9%, and more preferably 2 to 6% of the whole composition. When the blending amount is less than 0.1%, the stability of the component (A) is poor, and the actual feeling of retention in the oral cavity of the preparation is poor. As the compounding amount increases, the pharmaceutical stability decreases, and when it exceeds 9%, the pharmaceutical stability deteriorates.

It is preferable that the oral composition of the present invention further contains (D) a solid higher alcohol at 25 ° C. When the component (D) is blended, the stability of the preparation and the stability of the component (A) are further improved, and the feeling of retention in the oral cavity of the preparation is further enhanced.
Examples of the higher alcohol solid at 25 ° C. include higher alcohols having 16 to 22 carbon atoms, such as stearyl alcohol, cetanol, cetostearyl alcohol, and behenyl alcohol, and these may be used alone or in combination of two or more. Among them, higher alcohols having 16 to 18 carbon atoms, for example, stearyl alcohol, cetanol, and cetostearyl alcohol are preferable, and cetanol is more preferable. Specifically, for example, cetanol (melting point 47 to 53 ° C.) listed in the Japanese Pharmacopoeia is commercially available, and this can be used.

(D) When a solid higher alcohol is blended at 25 ° C., the blending amount of the entire composition is such that the stability of the preparation, the stability of the component (A), and the feeling of retention in the oral cavity of the preparation are improved. It is preferably 0.5 to 10%, more preferably 1 to 8%, still more preferably 3 to 6%.

Further, in (C) / (D) indicating the quantitative ratio of the component (C) and the component (D), the mass ratio is preferably 0.1 to 10, more preferably 0.5 to 8, and even more preferably 1. ~ 4. Within the above range, the stability of the pharmaceutical product and the actual feeling of retention in the oral cavity of the pharmaceutical product are further excellent.
Further, ((C) + (D)) / (B) indicating the ratio between the total amount of the components (C) and (D) and the amount of the component (B) is preferably 0.5 to 8 as a mass ratio. It is more preferably 0.5 to 5, still more preferably 0.7 to 4. Within the above range, the stability of the pharmaceutical product and the actual feeling of retention in the oral cavity of the pharmaceutical product are further remarkably excellent.

From the viewpoint of pharmaceutical stability, it is preferable to further add (E) anhydrous silicic acid to the oral composition of the present invention.
Examples of the (E) inorganic silicic acid include thickening anhydrous silicic acid such as thickening silica and thickening aluminum silica, and abrasive anhydrous silicic acid such as precipitation silica, aluminosilicate and zirconosilicate. In particular, it is preferable to use thickened anhydrous silicic acid, and thickened silica having a liquid absorption amount (45% glycerin aqueous solution) of 1.5 to 6 ml / g, particularly 2 to 5 ml / g can be used.
Specific examples of the silicic acid anhydride include Carplex # 67Q (absorbent amount of 2.3 ml / g thickening silica) manufactured by DSL Japan Co., Ltd. and AEROSIL 200 (absorbent liquid) manufactured by Nippon Aerosil Co., Ltd. Commercially available products such as (thickening silica having an amount of 4.3 ml / g) and Silicia 320 (thickening silica having a liquid absorption amount of 3.0 ml / g) manufactured by Fuji Silicia Chemical Co., Ltd. can be used.

(E) When the silicic acid anhydride is blended, the blending amount thereof is preferably 1 to 10%, more preferably 2 to 7%, still more preferably 3 to 5% of the whole composition.

The oral composition of the present invention is particularly suitable as a dentifrice composition for dentifrices, gelled dentifrices and the like. Further, in addition to the above-mentioned components, other known components can be blended as necessary within a range that does not interfere with the effects of the present invention. For example, in a dentifrice, an abrasive, a thickener, a binder, a surfactant, and if necessary, a colorant, a sweetener, a preservative, a fragrance, an active ingredient, and the like can be blended. The gel-like dentifrice usually does not contain an abrasive, but other compoundable components are the same as those of the dentifrice. The blending amount shown below is the blending amount with respect to the entire composition.

Examples of the abrasive include silicon dioxide, calcium phosphate-based compounds such as dihydrate calcium phosphate dihydrate or anhydrous, calcium carbonate, and synthetic resin-based abrasives.
The blending amount of the abrasive may be 0 to 50%, and when blended, it may be 2 to 50%, particularly 2 to 30%.
The oral composition of the present invention may be free of an abrasive, and is excellent in the stability of the component (A) and the stability of the formulation even without the abrasive.

Examples of the viscous agent include sugar alcohols such as sorbitol and xylit, and polyhydric alcohols such as glycerin and propylene glycol.
The blending amount of the thickener is usually 5 to 50%, particularly 10 to 30%.

As the binder, an organic binder can be blended. Examples thereof include cellulose derivatives such as hydroxyethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose and methyl cellulose, alginic acid derivatives, gums such as xanthan gum, sodium polyacrylate and carboxyvinyl polymers, especially in terms of formulation stability. , Cellulose derivatives are preferred. The blending amount of these binders is usually 0.1 to 10%, particularly 0.1 to 5%.

Any surfactant other than (B) nonionic surfactant can be used, and an anionic surfactant, a cationic surfactant, and an amphoteric surfactant can be blended.
Examples of the anionic surfactant include alkyl sulfates such as sodium lauryl sulfate, acyl sarcosates, acyl taurine salts, and acyl amino acid salts.
Examples of the cationic surfactant include an alkylammonium type and a quaternary ammonium salt such as an alkylbenzylammonium salt.
Examples of the amphoteric tenside include fatty acid amide propyl betaine such as alkyl betaine and coconut oil fatty acid amide propyl betaine, alkyl imidazolinium betaine, and 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine.
The blending amount of these arbitrary surfactants is preferably 0 to 10%, and when blended, it can be 0.001 to 10%, particularly 0.001 to 5%.

Examples of the colorant include Blue No. 1, Yellow No. 4, Titanium Dioxide and the like.
Examples of the sweetening agent include saccharin sodium and the like.
Examples of the preservative include paraoxybenzoic acid esters such as methylparaben (methyl paraoxybenzoate), benzoic acid or salts thereof.

Fragrances are peppermint oil, sparemint oil, anis oil, eucalyptus oil, winter green oil, cassia oil, clove oil, thyme oil, sage oil, lemon oil, orange oil, peppermint oil, cardamon oil, coriander oil, mandarin oil, lime. Oil, lavender oil, rosemary oil, laurel oil, camomill oil, caraway oil, majorum oil, bay oil, lemongrass oil, origanum oil, pine needle oil, neroli oil, rose oil, jasmine oil, grapefruit oil, sweetie oil , Yuzu oil, iris concrete, absolute peppermint, absolute rose, orange flower and other natural fragrances, and processing of these natural fragrances (front reservoir cut, rear reservoir cut, distilling, liquid extraction, essence, powder fragrance Perfume, menthol, carboxylic, anator, cineole, methyl salicylate, cinnamic aldehyde, eugenol, 3-l-mentoxypropane-1,2-diol, timole, linalol, linaryl acetate, limonene, etc. Menton, Menthylacetate, N-ethyl-paramentan-3-carboxamide, Pinen, Octylaldehyde, Citral, Pregon, Calvier acetate, Anisaldehyde, Ethylacetate, Ethylbutyrate, Allylcyclohexanepropionate, Methylanthranilate, Ethyl Single flavors such as methylphenylglycidate, vanillin, undecalactone, hexanal, butanol, isoamyl alcohol, hexenol, dimethylsulfide, cycloten, furfural, trimethylpyrazine, ethyllactate, ethylthioacetate, as well as strawberry flavor, apple flavor, banana Known perfume materials used in oral compositions such as flavors, pineapple flavors, grape flavors, mango flavors, butter flavors, milk flavors, fruit mix flavors, tropical fruit flavors and the like can be used in combination.
The blending amount of the fragrance is not particularly limited, but the blending amount of the above-mentioned fragrance material is preferably 0.000001 to 1%. The blending amount of the perfume for perfume using the above perfume material is preferably 0.1 to 2%, more preferably 0.2 to 1%.

As any active ingredient, an active ingredient acceptable for oral preparations can be used, for example, a nonionic bactericide such as isopropylmethylphenol, a cationic bactericide such as cetylpyridinium chloride, tranexamic acid, allantin, glycyrrhetinic acid and the like. Anti-inflammatory agents, enzymes such as dextranase, fluorine-containing compounds such as sodium fluoride, tin fluoride, sodium monofluorophosphate, water-soluble phosphate compounds, inorganic salts such as sodium chloride, potassium nitrate, aluminum lactate, ascorbin. Examples include, but are not limited to, acids, tocopherol acetates, plant extracts, anti-dental agents, anti-plaque agents. These active ingredients can be blended in an effective amount within a range that does not interfere with the effects of the present invention.

Hereinafter, the present invention will be specifically described with reference to Examples, Comparative Examples, and Prescription Examples, but the present invention is not limited to the following Examples. In the following examples,% indicates mass% unless otherwise specified.

[Examples, comparative examples]
Toothpaste compositions (dentifrices) having the compositions shown in Tables 1 to 3 were prepared by the following preparation methods and evaluated by the methods shown in (1) to (3) below. The results are also shown in the table.
How to prepare a dentifrice composition:
An oil layer containing a surfactant, an oil agent, and a hydrophobic component and an aqueous layer containing water, a hydrophilic component, and an inorganic powder are each heated to 60 ° C., cooled after emulsification, and a fragrance is added to prepare a dentifrice composition. Prepared.

(1) Evaluation method of pharmaceutical product stability 90 g of the dentifrice composition is filled in a general aluminum laminated tube container, stored at 60 ° C. for 1 month, and then the dentifrice composition is extruded from the tube container to obtain the pharmaceutical product stability (1). The lack of liquid separation) was evaluated according to the following evaluation criteria.
Evaluation criteria ☆: No liquid separation ◎: Liquid separation is only slightly observed in the mouth of the tube container ○: Liquid separation is slightly observed from the mouth to the inside of the tube container, but there is no problem ×: Liquid Significant separation is observed

(2) (A) Evaluation method of stability of vitamin B5 or its derivative 90 g of a dentifrice composition is filled in a general aluminum laminated tube container, stored at 60 ° C. for 1 month, and then subjected to high performance liquid chromatography (A). ) The residual amount of vitamin B5 or a derivative thereof was measured. The ratio (residual rate,%) of the content of the component (A) after storage at 60 ° C. for 1 month to the content (theoretical value) of the component (A) immediately after preparation of each dentifrice composition is calculated by the following formula. It was calculated and the stability (storage stability) of the component (A) was evaluated according to the following evaluation criteria.
In addition, the liquid separation was remarkably observed after storage at 60 ° C. for 1 month ((1) Evaluation result of pharmaceutical stability ×) The dentifrice composition has a non-uniform formulation, so the residual amount of the component (A) Was not measured, and the stability of the component (A) was not evaluated.
Panthenol survival rate (%) =
{(Content of (A) component after storage at 60 ° C for 1 month) / (Content of (A) component immediately after preparation (theoretical value))} × 100
Evaluation criteria ☆: 98% or more ◎: 95% or more and less than 98% ○: 90% or more and less than 95% ×: less than 90%

(3) Method for evaluating the actual feeling of retention in the oral cavity of the preparation Five expert panelists of the subjects evaluated the actual feeling of retention in the oral cavity of the dentifrice composition immediately after preparation.
1 g of the dentifrice composition was placed on a toothbrush (Clinica Advantage Toothbrush manufactured by Lion Corporation, 4-row compact normal type), and the teeth were brushed for 3 minutes by a usual method. The oral cavity was rinsed with water, and the actual feeling of retention felt in the oral mucosa immediately after use was judged according to the following scoring criteria.
Here, the actual feeling of retention in the oral cavity of the pharmaceutical product is a sensation that the oral mucosa is covered with the pharmaceutical product.
Scoring criteria 1: No feeling of staying 2: Almost no feeling of staying 3: Feeling of staying a little 4: Feeling of staying considerably 5: Feeling very feeling of staying 5 Calculate the average score of the score results , The actual feeling of retention of the pharmaceutical product was evaluated according to the following evaluation criteria.
Evaluation criteria (passed above ○)
☆: Average score of 5 people is 4.5 points or more ◎: Average score of 5 people is 4 points or more and less than 4.5 points ○: Average score of 5 people is 3 points or more and less than 4 points ×: Average score of 5 people Is less than 3 points

Details of the raw materials used are shown below. POE is an abbreviation for polyoxyethylene, and the value in parentheses after POE is the average number of moles of ethylene oxide added.
(A) Panthenol; manufactured by DSM Co., Ltd., Panthenol (B) POE (20) sorbitan monostearate; manufactured by Nippon Surfactant Industry Co., Ltd., TS-10MV
(B) Sorbitan monostearate; SS-10MV manufactured by Nippon Surfactant Industry Co., Ltd.
(B) POE (60) Hardened castor oil; manufactured by Nikko Chemicals Co., Ltd., HCO-60
Palm oil fatty acid amide propyl betaine (comparative product); TEGO BETAIN CK-OK manufactured by Degussa
(C) Light liquid paraffin; manufactured by Sanko Chemical Industry Co., Ltd., liquid paraffin No. 70-S
(C) Liquid paraffin; manufactured by Sanko Chemical Industry Co., Ltd., liquid paraffin No. 350S
Vaseline (comparative product); manufactured by Nikko Rica Co., Ltd., Sun White P-1
(D) Cetanol; manufactured by Kao Corporation, Nichikyoxetanol, "Japanese Pharmacopoeia Cetanol" (melting point 47-53 ° C)
(D) Stearyl alcohol; manufactured by Higher Alcohol Industry Co., Ltd., stearyl alcohol NX
(E) Silicic anhydride; manufactured by Nippon Aerosil Co., Ltd., AEROSIL 200
Hydroxyethyl cellulose 1; manufactured by Daicel FineChem Co., Ltd., HEC Daicel EE820
Hydroxyethyl Cellulose 2; Ashland Industries Netherlands BV, Nanosol 250 HX Pharma
Hydroxypropyl Methyl Cellulose; METOLOS E 90SH-4000SR manufactured by Shin-Etsu Chemical Co., Ltd.

＊；製剤が不均一であるため、（Ａ）成分の安定性は評価しなかった。

*; The stability of the component (A) was not evaluated because the formulation was non-uniform.

Next, a prescription example is shown. When the toothpaste of the formulation example was prepared and evaluated in the same manner using the same raw materials as those of the above example, (A) the stability of the component (storage stability) and the formulation stability were excellent, and the feeling that the formulation remained in the oral cavity was felt. Was also good.
(B) Sucrose fatty acid ester is manufactured by Mitsubishi Chemical Foods Co., Ltd., Surf Hope SE PHARMA J-1816, and (B) POE (20) Sorbitan monostearate is manufactured by Nippon Surfactant Industry Co., Ltd., TS- 10 MV was used.

[Prescription Example 1] Toothpaste (A) Panthenol 0.4
Glycyrrhetinic acid 0.4
Tocopherol acetate 2.0
(B) Sucrose fatty acid ester 2.0
(B) POE (20) Sorbitan monostearate 1.5
(B) Sorbitan monostearate 1.0
(C) Light liquid paraffin 4
(D) Cetanol 3
(E) Silicic anhydride 3.0
Hydroxyethyl cellulose 1 2.0
Sorbitol liquid (70%) 30
Methyl paraoxybenzoate 0.1
Ethanol 2.0
Sodium lauryl sulfate 2.0
Saccharin sodium hydrate 0.1
Fragrance 1.5
Purified water residue
100% in total
Mass ratio of (C) / (D); 1.3
((C) + (D)) / (B) mass ratio; 1.6

[Prescription Example 2] Toothpaste (A) Panthenol 0.4
Glycyrrhetinic acid 0.4
Cetylpyridinium Chloride Hydrate 0.05
(B) Sucrose fatty acid ester 2.0
(B) POE (20) Sorbitan monostearate 2.5
(B) Sorbitan monostearate 0.5
(C) Light liquid paraffin 5
(D) Cetanol 5
(E) Silicic anhydride 5.0
Hydroxyethyl cellulose 1 1.0
Hydroxypropyl Methyl Cellulose 1.5
Sorbitol liquid (70%) 10
Propylene glycol 5
Ethyl paraoxybenzoate 0.1
Sodium lauryl sulfate 1.0
Saccharin sodium hydrate 0.2
Fragrance 1.5
Purified water residue
100% in total
Mass ratio of (C) / (D); 1
((C) + (D)) / (B) mass ratio; 2.0

[Prescription Example 3] Toothpaste (A) Panthenol 0.3
Glycyrrhetinic acid 0.3
Tocopherol acetate 2.0
Cetylpyridinium Chloride Hydrate 0.05
(B) Sucrose fatty acid ester 2.0
(B) POE (20) Sorbitan monostearate 1.5
(B) Sorbitan monostearate 1.0
(C) Light liquid paraffin 2.0
(D) Cetanol 1.4
(E) Silicic anhydride 3.0
Hydroxyethyl cellulose 2 1.5
Hydroxypropyl Methyl Cellulose 0.5
Sorbitol liquid (70%) 20
Propylene glycol 5
Methyl paraoxybenzoate 0.1
Ethyl paraoxybenzoate 0.1
Sodium lauryl sulfate 1.6
Saccharin sodium hydrate 0.2
Ethanol 1.0
Fragrance 1.5
Purified water residue
100% in total
Mass ratio of (C) / (D); 1.4
((C) + (D)) / (B) mass ratio; 0.8

[Prescription Example 4] Toothpaste (A) Panthenol 0.3
Glycyrrhetinic acid 0.3
Tocopherol acetate 2.0
Cetylpyridinium Chloride Hydrate 0.05
(B) Sucrose fatty acid ester 2.0
(B) POE (20) Sorbitan monostearate 1.5
(B) Sorbitan monostearate 1.0
(C) Light liquid paraffin 2.0
(D) Cetanol 1.4
(E) Silicic anhydride 3.0
Hydroxyethyl cellulose 2 1.5
Hydroxypropyl Methyl Cellulose 1.0
Sorbitol liquid (70%) 20
Propylene glycol 5
Methyl paraoxybenzoate 0.1
Ethyl paraoxybenzoate 0.1
Sodium lauryl sulfate 0.8
Saccharin sodium hydrate 0.2
Ethanol 1.0
Fragrance 1.5
Purified water residue
100% in total
Mass ratio of (C) / (D); 1.4
((C) + (D)) / (B) mass ratio; 0.8

[Prescription Example 5] Toothpaste (A) Panthenol 0.3
Glycyrrhetinic acid 0.3
Tocopherol acetate 2.0
Cetylpyridinium Chloride Hydrate 0.05
(B) Sucrose fatty acid ester 2.0
(B) POE (20) Sorbitan monostearate 1.5
(B) Sorbitan monostearate 1.0
(C) Light liquid paraffin 4.0
(D) Cetanol 1.4
(E) Silicic anhydride 3.0
Hydroxyethyl cellulose 2 1.5
Hydroxypropyl Methyl Cellulose 0.5
Sorbitol liquid (70%) 20
Propylene glycol 5
Methyl paraoxybenzoate 0.1
Ethyl paraoxybenzoate 0.1
Sodium lauryl sulfate 1.6
Saccharin sodium hydrate 0.2
Ethanol 1.0
Fragrance 1.5
Purified water residue
100% in total
Mass ratio of (C) / (D); 1.4
((C) + (D)) / (B) mass ratio; 1.2

[Prescription Example 6] Toothpaste (A) Panthenol 0.3
Glycyrrhetinic acid 0.3
Tocopherol acetate 2.0
Cetylpyridinium Chloride Hydrate 0.05
(B) Sucrose fatty acid ester 2.0
(B) POE (20) Sorbitan monostearate 1.5
(B) Sorbitan monostearate 1.0
(C) Light liquid paraffin 2.0
(D) Cetanol 1.4
(E) Silicic anhydride 3.0
Hydroxyethyl cellulose 1 1.5
Hydroxypropyl Methyl Cellulose 1.0
Sorbitol liquid (70%) 20
Propylene glycol 5
Methyl paraoxybenzoate 0.1
Ethyl paraoxybenzoate 0.1
Sodium lauryl sulfate 1.6
Saccharin sodium hydrate 0.15
Ethanol 1.0
Fragrance 1.5
Purified water residue
100% in total
Mass ratio of (C) / (D); 1.4
((C) + (D)) / (B) mass ratio; 0.8

[Prescription Example 7] Toothpaste (A) Panthenol 0.3
Glycyrrhetinic acid 0.3
Tocopherol acetate 2.0
Cetylpyridinium Chloride Hydrate 0.05
(B) Sucrose fatty acid ester 2.0
(B) POE (20) Sorbitan monostearate 1.5
(B) Sorbitan monostearate 1.0
(C) Light liquid paraffin 4.0
(D) Cetanol 1.4
(E) Silicic anhydride 3.0
Hydroxyethyl cellulose 2 1.5
Hydroxypropyl Methyl Cellulose 1.0
Sorbitol liquid (70%) 20
Propylene glycol 5
Methyl paraoxybenzoate 0.1
Ethyl paraoxybenzoate 0.1
Sodium lauryl sulfate 1.6
Saccharin sodium hydrate 0.2
Ethanol 1.0
Fragrance 1.5
Purified water residue
100% in total
Mass ratio of (C) / (D); 1.4
((C) + (D)) / (B) mass ratio; 1.2

[Prescription Example 8] Toothpaste (A) Panthenol 0.3
Glycyrrhetinic acid 0.3
Tocopherol acetate 2.0
Cetylpyridinium Chloride Hydrate 0.05
(B) Sucrose fatty acid ester 2.0
(B) POE (20) Sorbitan monostearate 1.5
(B) Sorbitan monostearate 1.0
(C) Light liquid paraffin 2.0
(D) Cetanol 1.4
(E) Silicic anhydride 3.0
Hydroxyethyl cellulose 2 2.0
Hydroxypropyl Methyl Cellulose 0.5
Sorbitol liquid (70%) 20
Propylene glycol 5
Methyl paraoxybenzoate 0.1
Ethyl paraoxybenzoate 0.1
Sodium lauryl sulfate 1.6
Saccharin sodium hydrate 0.2
Ethanol 1.0
Fragrance 1.5
Purified water residue
100% in total
Mass ratio of (C) / (D); 1.4
((C) + (D)) / (B) mass ratio; 1.2

Claims (9)

(A) Vitamin B5 or its derivatives,
An oral composition comprising (B) a nonionic surfactant and (C) a hydrocarbon oil liquid at 25 ° C., and containing 0.1 to 9% by mass of the component (C). .. The oral composition according to claim 1, wherein the content of the component (A) is 0.1 to 5% by mass, and the content of the component (B) is 0.5 to 10% by mass. (D) The oral composition according to claim 1 or 2, which contains a solid higher alcohol at 25 ° C. (D) The oral composition according to claim 3, wherein the content of the component is 0.5 to 10% by mass. The oral composition according to claim 3 or 4, wherein (C) / (D) is 0.1 to 10 in mass ratio. The oral composition according to any one of claims 3 to 5, wherein ((C) + (D)) / (B) is 0.5 to 8 as a mass ratio. The oral composition according to any one of claims 1 to 6, further comprising (E) silicic anhydride. (E) The oral composition according to claim 7, wherein the content of the component is 1 to 10% by mass. The oral composition according to any one of claims 1 to 8, which is a dentifrice composition.